← All trials
NCT05018221
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2021
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Aug 24, 2021
- Last posted
- Oct 20, 2021
- Enrollment
- 350
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of SydneyLead sponsor
- Salford Royal Foundation NHS TrustCollaborator
- University of SydneyStudy chair
- Waitemata District Health BoardCollaborator
- Australasian Kidney Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.